drugset / Trial / NCT00251238

Efficacy and Tolerability of Ginkgo Biloba Extract in Patients With Raynaud´s Phenomenon

NCT00251238

Phase 2 Completed 41 enrolled VSM Geneesmiddelen b.v.
RandomizedParallel-groupQuadruple-blindDiagnostic

Summary

The aim of the study is to investigate the efficacy and safety of EGb 761® in patients with the primary Raynaud phenomenon, with regards to the frequency, duration and severity of vasospastic attacks.

Timeline

Start
2005-11
Primary completion
2006-03
Completion
2006-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Ginkgo Biloba Extract Traditional medicine (herbal / TCM)

Indications